Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-08-09
2009-12-15
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C435S338000, C435S007230, C530S388800
Reexamination Certificate
active
07632498
ABSTRACT:
Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
REFERENCES:
patent: WO 2005/095964 (2005-10-01), None
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Freeman et al. (Clin. Can. Res. 5:2121-2132 (1999)).
Williams et al. (PNAS 95:14932-14937 (1998)).
Hiraiwa et al. (Int. J. Cancer (Pred. Oncol.) 74:180-184 (1997)).
Neomarkers data sheet for MCM7 (Lab Vision pp. 1-2).
CDC47/ MCM7 Ab2 data sheet (Lab Vision pp. 1-3).
Campbell et al, Biology, 5th ed. p. 856, 1999.
Brake, T., et al., “Comparative Analysis of Cervical Cancer in Women and in a Human Papillomavirus-Transgenic Mouse Model: Identification ofMinichromosome Maintenance Protein 7as an Informative Biomarker for Human Cervical Cancer”,Cancer Research, Dec. 2003, pp. 8173-8180, vol. 63.
Grunicke, H.H., et al., “Role and Characterization of Protein Kinase C Isoforms Implicated in the Transcriptional Activation of Cyclin D1 by Transforming HA-RAS”,Cell Biology International, 2001, A16-A17, vol. 25.
Heidebrecht, H.J., et al. “Ki-Mcm6 a Monoclonal Antibody Specific for the Human Minichromosome Maintenance Protein 6 (Mcm6)”,Joint Annual Meeting, 2000, p. 406, University of Kiel and University ofHamburg, Germany.
Helfenstein, A., et al., “Minichromosome Maintenance Protein (MCM6) in Low-Grade Chondrosarcoma”,Am. J. Clin. Pathology, 2004, pp. 912-918, vol. 122.
Ishimi Y., et al., “Enhanced Expression of Mcm Proteins in Cancer Cells Derived from Uterine Cervix”,Eur. J. Biochem., Feb. 2003, pp. 1089-1101, vol. 270.
Malinowski D.P., “Molecular diagnostic Assays for Cervical Neoplasia: Emerging Markers for the Detection of High-Grade Cervical Disease”,BioTechniques, Apr. 2005, pp. 17-23, vol. 38.
Schrader, C., et al., “Minichromosome Maintenance Protein 6, a Proliferation Marker Superior to Ki-67 and Independent Predictor of Survival in Patients with Mantle Cell Lymphoma”,British Journal of Cancer, 2005, pp. 939-945, vol. 93.
Fischer Timothy J.
Malinowski Douglas P.
Taylor Adriann J.
Alston & Bird LLP
Bristol Lynn
TriPath Imaging, Inc.
LandOfFree
MCM6 and MCM7 monoclonal antibodies and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCM6 and MCM7 monoclonal antibodies and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCM6 and MCM7 monoclonal antibodies and methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091531